AI summary · DOI: 10.64898/2026.11.10.765512 · bioRxiv: Bioengineering

Engineered endocrine objects tolerate hypoxia in macroencapsulation devices and enable subcutaneous engraftment in diabetic mice

K. Wang, K. Okada, M. Jin, J. Deng, B. Wang, J. A. Flanders, P. L. Tran, M. Lee,
and 1 more authorM. Ma
Original paper Published on 12 Nov. 2026 bioRxiv preprint License: not stated (all rights reserved) Also in: fr

How to read this summary? Illustrated guide

The essentials

Small engineered endocrine objects showed greater hypoxia tolerance than native islets and maintained glycemic control after subcutaneous macroencapsulation in diabetic mice.

Based on the abstract only: check the details in the original paper.

Question

Can engineered endocrine objects (EEOs) withstand the low-oxygen conditions caused by macroencapsulation and support subcutaneous transplantation without immunosuppression? The study addresses central necrosis and poor mass transfer as constraints on encapsulated islet survival.

Method

The researchers produced EEOs by mesh-induced fragmentation of native islets followed by recovery culture; objects were as small as approximately 47 μm. They compared EEO and native-islet viability after 24 hours at 1% oxygen and transplanted 300 islet equivalents of rat EEOs in a 0.5-mm-thick alginate-based macroencapsulation device into immunocompetent diabetic mice.

Findings

  • Result After 24 hours at 1% oxygen, EEO viability exceeded 90%, compared with 49% for native islets.
    See the passage in the paper
    Under hypoxic culture condition (1% O2 for 24 hours), EEOs showed enhanced viability of >90%, compared to 49% for the native islet control.
  • Result A marginal dose of encapsulated rat EEOs achieved glycemic control for more than five weeks in diabetic mice.
    See the passage in the paper
    With a flat, thin (0.5-mm-thick) alginate-based macroencapsulation device, rat EEOs at a marginal dose of 300 islet equivalents (IEQ) achieved glycemic control for over 5 weeks in the challenging, hypoxic subcutaneous space of immunocompetent diabetic mice.
  • Result Engrafted mice had near-physiological glycemic profiles after glucose challenge.
    See the passage in the paper
    The engrafted mice displayed near-physiological glycemic profiles upon glucose challenge, and the retrieved EEOs showed enhanced viability with significantly reduced central necrosis compared with native islets.
  • Authors’ interpretation The authors propose hypoxia-resistant engineered cell products as a way to address a key constraint of encapsulation devices.
    See the passage in the paper
    Overall, engineering hypoxia-resistance into cellular products mitigates intrinsic constraints of encapsulation devices, offering a promising strategy for convenient, immunosuppression-free subcutaneous islet transplantation.

Limitations

  • The reported evidence is limited to hypoxia culture testing and transplantation in diabetic mice; the abstract does not report human transplantation outcomes.

Why it matters

The authors argue that engineering islet-derived products for hypoxia resistance could mitigate the poor mass transfer and central necrosis associated with encapsulation. They present this as a potential route to convenient, immunosuppression-free subcutaneous transplantation.

Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.

AI-generated keywords: islet transplantation engineered endocrine objects macroencapsulation hypoxia tolerance subcutaneous grafts

Read further

  • Comprehensive Summary
  • Layman's Summary
  • Blog article
  • Original abstract
The paper addresses a central challenge in islet transplantation: macroencapsulation devices can shield transplanted insulin-producing cells from immune-cell contact, potentially avoiding the need for immunosuppressive treatment. However, these devices also prevent blood vessels from growing into the graft. Limited oxygen and nutrient delivery can therefore cause cell death, particularly in the center of an islet. The authors investigated whether engineered endocrine objects (EEOs)—smaller cell clusters designed to better tolerate low oxygen—could perform better than intact islets in an encapsulation device and support transplantation under the skin. To create EEOs, the researchers passed native islets through a mesh to fragment them, then cultured the fragments to allow recovery. The abstract reports that the process was scalable and reproducible and produced objects as small as approximately 47 micrometers. The approach is motivated by observations that larger islets—roughly those above 40 micrometers—are vascularized in a healthy pancreas, while smaller endocrine-cell clusters can exist without internal capillaries. The study compared EEOs with native islets under hypoxia, using 1% oxygen for 24 hours. It also tested whether rat EEOs could restore glycemic control after implantation in a flat, thin, alginate-based macroencapsulation device. The device was 0.5 millimeters thick, and the grafts were placed in the subcutaneous space of immunocompetent diabetic mice. After the 24-hour hypoxia challenge, EEO viability exceeded 90%, compared with 49% for native islets. The abstract thus reports substantially improved survival under low-oxygen conditions following fragmentation and recovery culture. In the transplantation experiment, a marginal dose of 300 islet equivalents of rat EEOs maintained glycemic control in mice for more than five weeks. Recipients also showed near-physiological glycemic profiles during glucose challenge. At retrieval, EEO grafts had higher viability and significantly less central necrosis than native-islet grafts, although the abstract does not provide numerical values for these comparisons. The authors conclude that engineering smaller, hypoxia-tolerant endocrine-cell products may address a major limitation of encapsulation: restricted oxygen and nutrient transport when grafts lack internal blood vessels. Their findings support the possibility of subcutaneous, immunosuppression-free islet transplantation using a thin macroencapsulation device. They also suggest that adapting the cell product to the device’s low-oxygen environment may be as important as the device design itself. The available evidence is limited to the title and abstract; the full text was not available under the supplied license. As a result, key details for evaluating the strength and scope of the findings are unavailable, including sample sizes, statistical methods, transplantation control-group design, insulin-production measures, and follow-up conditions beyond the reported period. The abstract also does not establish long-term graft safety, durability, or efficacy in humans, or demonstrate that the approach eliminates immune responses or other transplantation risks. These are promising preclinical findings in diabetic mice, not evidence of established clinical effectiveness.

Was this synthesis useful?

Score: 0

Why do we need votes?

Votes are used to determine whether we need to re-run our summarizing tools. If the count reaches -10, our tools can be restarted.

Ask questions about this paper to our AI assistant

How to chat with this paper? Illustrated guide

You can also chat with multiple papers at once here.

⚠The license of the paper does not allow us to build upon its content and the AI assistant only knows about the paper metadata rather than the full article.

Figures and plots

Ask about a figure by number or use its question button to request visual analysis. Up to two figures and four image panels per question. Values read from plots are approximate; check the original data.

AI assistant instructions?

Tools for this paper

Explain it differently 1 free rewrite left today
Save to a collection Group papers in collections to compare them, chat with them and export them. Continue with Google Create a free account Log in

Advanced tools Premium

For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium

Zotero Zotero guide
Citation alerts Citation alerts guide
Weekly letter Presented in "Biology and medicine this week" of 16 November 2026. Biology and medicine this week: New jobs for cells, enzymes and genes · Receive one by email for free

Papers around this one

See them on a map

Ranked by how close their title and abstract are to this paper’s. Select some to read them together.

Closest papers

  1. Very close Broader context
    Bridging scale-up to transplantation: pluripotent stem cell-derived pancreatic islet encapsulation in emulsion-generated high concentration alginate beads
    Arianna Castro Rojas, J. Brassard, Marie Billaud et al. · 2026 · bioRxiv · preprint, not peer reviewed · Not summarized yet

    This study encapsulates stem-cell-derived islet-like clusters in concentrated alginate beads, addressing scale-up and graft survival rather than hypoxia-resistant engineered endocrine objects.

    Abstract

    Pluripotent stem cell-derived pancreatic islet-like cell clusters (SC-islets) have emerged as potential cellular therapy for type 1 diabetes. While SC-islets can theoretically be produced in bioreactors to meet transplantation needs of many recipients per batch, biomanufacturing and translational challenges remain. SC-islet can be cultured in suspension using stirred tank or vertical wheel bioreactors, but these can impart hydrodynamic damage and lead to cellular agglomeration, particularly upon scale-up. We previously described a robust emulsion-based process to encapsulate murine pancreatic beta cells in high-concentration alginate beads which improved graft survival in allogeneic recipien…

  2. Very close Review
    Safe host integration in islet tissue engineering for Type 1 Diabetes Mellitus: emerging technologies and a constraint-guided hybrid islet framework
    Wallace Lung · 2026 · Journal of high school science · Not summarized yet

    This review surveys islet tissue-engineering strategies and proposes a hybrid framework for balancing immune protection, oxygen delivery, fibrosis, and host integration.

    Abstract

    Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic β cells and requires lifelong insulin replacement. Islet transplantation can restore endogenous insulin secretion, but donor scarcity, immune rejection, early graft loss, inadequate oxygen delivery, and fibrosis limit its application. This review examines conventional and emerging islet tissue-engineering approaches and proposes a conceptual hybrid bio-artificial islet system (HBAIS). A heuristic constraint-exchange framework compares the functions gained from successive technological additions with their associated risks, overlapping benefits, and operational dependencies. The analysis identifies hypoimmune st…

  3. Very close Another approach to the problem
    Microgels Containing Protease Resistant CXCL12 and FasL Enable Long-term Allo-Islet Function Without Systemic Immunosuppression.
    F. Doğan, Assia El Babsiri, Esin Ozkan et al. · 2026 · Diabetes · Not summarized yet

    This study uses FasL- and CXCL12-coated microgels to locally immunomodulate allogeneic islet grafts, reporting sustained function without systemic immunosuppression.

    Abstract

    ARTICLE HIGHLIGHTS Cotransplantation of allogeneic islets with microgels coated with streptavidin fused with Fas ligand and protease-resistant CXCL12 results in robust and sustained diabetes reversal for over 6 months in streptozotocin-induced diabetic mice and induces local immunomodulation, enhances Treg recruitment within the graft, and improves graft vascularization. This study addresses a critical challenge in cell transplantation, namely the need to develop technologies that enable local immunoprotection of the graft while eliminating the need for systemic immunosuppression. This combination microgel technology could offer a more favorable risk-benefit profile by reducing infection ris…

  4. Close Another approach to the problem
    Combined B2M Knockout and Alginate Encapsulation Reduces Immune Rejection of iPSC-Derived Pancreatic Progenitors
    P. Ermakova, A. Barinova, Alexandra Y. Bogomolova et al. · 2026 · Cells · Not summarized yet

    This study combines alginate encapsulation with B2M knockout to reduce immune rejection of iPSC-derived pancreatic progenitors.

    Abstract

    Allogeneic cell replacement therapy for diabetes using induced pluripotent stem cell (iPSC)-derived pancreatic progenitors (PPs) is currently limited by immune rejection. Alginate encapsulation and the genetic ablation of HLA-I via β2-microglobulin (B2M) knockout represent distinct strategies to reduce immune recognition and to protect the transplanted cells. We generated encapsulated B2M-knockout pancreatic progenitors (IPS-∆B2M-PPs) and evaluated their immunogenicity in vitro using each of: peripheral blood mononuclear cell (PBMC) co-culture, natural killer cell (NK cell) degranulation, T-cell activation, and rat macrophage adhesion. In vivo studies were also performed to assess capsule bi…

  5. Close Broader context
    The capsule was never just a capsule: what islet encapsulation is for, now that immunoisolation is no longer its job
    A. Citro, Lorenzo Piemonti · 2026 · Frontiers in Bioengineering and Biotechnology · Not summarized yet

    This article argues that encapsulation must balance immune exclusion with transport, dose, host integration, durability, and retrieval, extending beyond the hypoxia constraint examined here.

    Abstract

    For more than four decades, islet encapsulation has been defined by a single objective: to immunoprotect transplanted cells while preserving glucose sensing and insulin delivery, thereby eliminating systemic immunosuppression. No passive device has yet achieved that objective with reproducible, durable and clinically meaningful efficacy. The central limitation is not simply the absence of an optimal polymer, but an over-constrained architecture in which immune exclusion, molecular transport, therapeutic cell dose, host integration, mechanical durability and retrieval must be solved simultaneously. The clinical contrast between sealed and vascularly accessible devices makes this coupling visi…

  6. Close Another approach to the problem
    Graft Localized Immunomodulation with Rapamycin-Eluting PLGA Microparticles Promotes Murine Islet Allograft Survival and Induces Operational Tolerance.
    Jordan Wong, Purushothaman Kuppan, Nerea Cuesta-Gomez et al. · 2026 · American Journal of Transplantation · Not summarized yet

    This study uses rapamycin-releasing PLGA microparticles to locally suppress immune responses and prolong murine islet allograft survival.

    Abstract

    Islet transplantation effectively restores physiologic glycemic regulation in a subset of individuals living with type 1 diabetes; however, lifelong systemic immunosuppression remains a major barrier to broader patient inclusion. Herein, we explored the use of a localized drug delivery system to preserve islet allograft function, circumventing systemic immunosuppression. Rapamycin (Rapa) was effectively encapsulated within poly(lactic-co-glycolic acid) microparticles (MP), which facilitated sustained and localized drug release to the islet grafts, modulating the immune environment and significantly prolonging allograft survival (p<0.05). Long-term outcomes were further enhanced when Rapa-MP …

  7. Close Same question
    Organotypic vascularization improves maturation of human stem cell-derived islets and restores normoglycemia in diabetic mice.
    Jing-Qiang Wang, A. Pélissier, Jeffrey S. H. Lin et al. · 2026 · Cell Stem Cell · cited 1 time · Not summarized yet

    This study also addresses poor islet graft survival from inadequate oxygenation, using vascularized stem-cell-derived organoids to improve hypoxia resistance and restore normoglycemia.

    Abstract

    Human pluripotent stem cells-derived pancreatic islet organoids (PIOs) hold promise for treating type 1 diabetes, but poor post-transplant survival due to inadequate vascularization remains a major challenge. Here, we generated vascularized PIOs (VPIOs) by co-culturing PIOs with blood vessel organoids (BVOs), resulting in integrated structures with BVOs-derived capillary networks that penetrate into the islet structures. These blood vessels structurally exhibit fenestrations characteristic of islet-specific endothelium and carry a molecular signature of organotypic vasculature. β cells within the VPIOs display partially enhanced maturation and greater resistance to hypoxia and endoplasmic re…

  8. Close Broader context
    High‐Density Dynamic Culture of Neonatal Porcine Islets Improves Islet Recovery and Function Post‐Transplantation
    Summer A. Helmi, Chelsea Castro, Soren Stachniak et al. · 2026 · Xenotransplantation · Not summarized yet

    The study optimizes dynamic culture of neonatal porcine islets for scalable production and post-transplant function, rather than hypoxia-tolerant encapsulated grafts.

    Abstract

    ABSTRACT Introduction Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic β‐cells, necessitating lifelong exogenous insulin therapy. Scalable β‐cell replacement strategies are needed to reproducibly increase ß cell production. Neonatal porcine islets (NPIs) are a promising xenogeneic source of ß cells; however, limited manufacturing scalability hinders clinical translation. This study optimizes a dynamic culture system to assess its potential for scalable NPIs production for clinical translation. Methods NPIs were cultured under three conditions: static suspension and dynamic suspension in a PBS Mini Vertical‐Wheel bioreactor at 4.5K (Bio 4.5) and 6.0K (Bio 6.0) NPIs/ml. …

How are these papers found?

We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.

Updated on 16 November 2026.

The illustrated guide to the papers around a paper

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.